<p>Zentalis Pharmaceuticals（纳斯达克代码：ZNTL - 获取免费报告）在周日发布的研究报告中被 Wall Street Zen 的分析师从 “卖出” 评级上调至 “持有” 评级。</p>
<p>其他几家券商最近也对 ZNTL 发布了报告。Wedbush 在 11 月 11 日的报告中重申了 “中性” 评级，并将 Zentalis Pharmaceuticals 的目标价设定为 4.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了 Zentalis Pharmaceuticals 的 “卖出（e+）” 评级。Wells Fargo &amp; Company 在 8 月 7 日的报告中将 Zentalis Pharmaceuticals 的目标价从 6.00 美元下调至 5.00 美元，并为该公司设定了 “等权重” 评级。HC Wainwright 在 8 月 7 日的报告中将 Zentalis Pharmaceuticals 的评级上调至 “强力买入”。最后，Leerink Partners 在周二的研究笔记中重新发布了 “市场表现” 评级，并将 Zentalis Pharmaceuticals 的目标价设定为 2.00 美元。一位分析师给予该股票 “强力买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价为 4.53 美元。</p>
<p><strong>查看我们关于 Zentalis Pharmaceuticals 的最新股票报告</strong></p>
<h2>Zentalis Pharmaceuticals 价格表现</h2>
<p>纳斯达克 ZNTL 的股票在周五开盘价为 1.33 美元。该公司的市值为 9609 万美元，市盈率为-0.64，贝塔值为 1.87。该股票的 50 日移动平均线为 1.52 美元，200 日移动平均线为 1.45 美元。Zentalis Pharmaceuticals 的 1 年最低价为 1.01 美元，1 年最高价为 4.00 美元。</p>
<p>Zentalis Pharmaceuticals（纳斯达克代码：ZNTL - 获取免费报告）最近在 11 月 10 日发布了季度财报。该公司报告每股收益为（0.37 美元），超出市场共识预期的（0.49 美元）0.12 美元。股票研究分析师预计 Zentalis Pharmaceuticals 在当前财政年度的每股收益将为-2.42 美元。</p>
<h2>对 Zentalis Pharmaceuticals 的对冲基金看法</h2>
<p>对冲基金最近调整了对该公司的持股。Catalyst Funds Management Pty Ltd 在第二季度购买了 Zentalis Pharmaceuticals 的新股份，价值约为 31,000 美元。Cerity Partners LLC 在第一季度将其在 Zentalis Pharmaceuticals 的持股增加了 58.7%。Cerity Partners LLC 现在拥有该公司 20,501 股股票，价值 33,000 美元，此前在上个季度购买了 7,579 股。Qube Research &amp; Technologies Ltd 在第二季度收购了 Zentalis Pharmaceuticals 的新股份，价值约为 37,000 美元。Y Intercept Hong Kong Ltd 在第二季度购买了 Zentalis Pharmaceuticals 的新股份，价值约为 38,000 美元。最后，Corient Private Wealth LLC 在第二季度购买了 Zentalis Pharmaceuticals 的新股份，价值约为 41,000 美元。</p>
<h2>关于 Zentalis Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Zentalis Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现和开发小分子治疗药物，以治疗各种癌症。其产品候选药物包括 ZN-c3，这是一种 WEE1 抑制剂，针对晚期实体肿瘤和血液恶性肿瘤的治疗；目前正在进行针对子宫浆液性癌症的单药治疗的二期临床试验；在 Cyclin E1 驱动的高等级浆液性卵巢癌、输卵管癌或原发性腹膜癌的二期临床试验；与 PARPi 联合治疗铂耐药卵巢癌的 1/2 期临床试验；与化疗联合治疗铂耐药卵巢癌、腹膜癌或输卵管癌的 1b 期临床试验；与化疗联合治疗复发或难治性骨肉瘤的 1/2 期临床试验；与 encorafenib 和 cetuximab 联合治疗突变转移性结直肠癌的 1/2 期临床试验；以及与化疗联合治疗胰腺癌的 1/2 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Zentalis Pharmaceuticals 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Meta 的痛苦可能是你的收益：这是一个罕见的买入窗口吗？</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>3 只低调的 AI 股票在下跌时值得购买</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>你的感恩节投资计划：3 只股票将受益于足球热潮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Zentalis Pharmaceuticals 吗？</h2>
<p>在你考虑 Zentalis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Zentalis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Zentalis Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ZNTL

<p>华尔街禅将 Zentalis Pharmaceuticals（纳斯达克代码：ZNTL）的评级从 “卖出” 上调至 “持有”。其他分析师的评级各不相同，其中一位为 “强烈买入”，五位为 “持有”，一位为 “卖出”。该股票的共识评级为 “持有”，平均目标价为 4.53 美元。Zentalis 专注于开发癌症治疗药物，并有多个正在进行的临床试验。对冲基金最近调整了在该公司的持股</p>

<p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) was upgraded by analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report issued on Sunday.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals（纳斯达克代码：ZNTL - 获取免费报告）在周日发布的研究报告中被 Wall Street Zen 的分析师从 “卖出” 评级上调至 “持有” 评级。</p>
</div><p>Several other brokerages have also recently issued reports on ZNTL. Wedbush reaffirmed a &#34;neutral&#34; rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. Wells Fargo &amp; Company dropped their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, August 7th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Thursday, August 7th. Finally, Leerink Partners reissued a &#34;market perform&#34; rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $4.53.</p>
<div class="lb-trans"><p>其他几家券商最近也对 ZNTL 发布了报告。Wedbush 在 11 月 11 日的报告中重申了 “中性” 评级，并将 Zentalis Pharmaceuticals 的目标价设定为 4.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了 Zentalis Pharmaceuticals 的 “卖出（e+）” 评级。Wells Fargo &amp; Company 在 8 月 7 日的报告中将 Zentalis Pharmaceuticals 的目标价从 6.00 美元下调至 5.00 美元，并为该公司设定了 “等权重” 评级。HC Wainwright 在 8 月 7 日的报告中将 Zentalis Pharmaceuticals 的评级上调至 “强力买入”。最后，Leerink Partners 在周二的研究笔记中重新发布了 “市场表现” 评级，并将 Zentalis Pharmaceuticals 的目标价设定为 2.00 美元。一位分析师给予该股票 “强力买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价为 4.53 美元。</p>
</div><p><strong>View Our Latest Stock Report on Zentalis Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Zentalis Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Zentalis Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 价格表现</h2>
</div><p>Shares of NASDAQ ZNTL opened at $1.33 on Friday. The company has a market cap of $96.09 million, a price-to-earnings ratio of -0.64 and a beta of 1.87. The stock's 50-day moving average is $1.52 and its two-hundred day moving average is $1.45. Zentalis Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $4.00.</p>
<div class="lb-trans"><p>纳斯达克 ZNTL 的股票在周五开盘价为 1.33 美元。该公司的市值为 9609 万美元，市盈率为-0.64，贝塔值为 1.87。该股票的 50 日移动平均线为 1.52 美元，200 日移动平均线为 1.45 美元。Zentalis Pharmaceuticals 的 1 年最低价为 1.01 美元，1 年最高价为 4.00 美元。</p>
</div><p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.12. Equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals（纳斯达克代码：ZNTL - 获取免费报告）最近在 11 月 10 日发布了季度财报。该公司报告每股收益为（0.37 美元），超出市场共识预期的（0.49 美元）0.12 美元。股票研究分析师预计 Zentalis Pharmaceuticals 在当前财政年度的每股收益将为-2.42 美元。</p>
</div><h2>Hedge Funds Weigh In On Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Zentalis Pharmaceuticals 的对冲基金看法</h2>
</div><p>Hedge funds have recently modified their holdings of the company. Catalyst Funds Management Pty Ltd bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $31,000. Cerity Partners LLC raised its position in Zentalis Pharmaceuticals by 58.7% in the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock worth $33,000 after purchasing an additional 7,579 shares during the last quarter. Qube Research &amp; Technologies Ltd acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $37,000. Y Intercept Hong Kong Ltd bought a new position in Zentalis Pharmaceuticals during the second quarter worth about $38,000. Finally, Corient Private Wealth LLC bought a new position in Zentalis Pharmaceuticals during the second quarter worth about $41,000.</p>
<div class="lb-trans"><p>对冲基金最近调整了对该公司的持股。Catalyst Funds Management Pty Ltd 在第二季度购买了 Zentalis Pharmaceuticals 的新股份，价值约为 31,000 美元。Cerity Partners LLC 在第一季度将其在 Zentalis Pharmaceuticals 的持股增加了 58.7%。Cerity Partners LLC 现在拥有该公司 20,501 股股票，价值 33,000 美元，此前在上个季度购买了 7,579 股。Qube Research &amp; Technologies Ltd 在第二季度收购了 Zentalis Pharmaceuticals 的新股份，价值约为 37,000 美元。Y Intercept Hong Kong Ltd 在第二季度购买了 Zentalis Pharmaceuticals 的新股份，价值约为 38,000 美元。最后，Corient Private Wealth LLC 在第二季度购买了 Zentalis Pharmaceuticals 的新股份，价值约为 41,000 美元。</p>
</div><h2>About Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Zentalis Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现和开发小分子治疗药物，以治疗各种癌症。其产品候选药物包括 ZN-c3，这是一种 WEE1 抑制剂，针对晚期实体肿瘤和血液恶性肿瘤的治疗；目前正在进行针对子宫浆液性癌症的单药治疗的二期临床试验；在 Cyclin E1 驱动的高等级浆液性卵巢癌、输卵管癌或原发性腹膜癌的二期临床试验；与 PARPi 联合治疗铂耐药卵巢癌的 1/2 期临床试验；与化疗联合治疗铂耐药卵巢癌、腹膜癌或输卵管癌的 1b 期临床试验；与化疗联合治疗复发或难治性骨肉瘤的 1/2 期临床试验；与 encorafenib 和 cetuximab 联合治疗突变转移性结直肠癌的 1/2 期临床试验；以及与化疗联合治疗胰腺癌的 1/2 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Zentalis Pharmaceuticals</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>3 Under-the-Radar AI Stocks to Buy on the Dip</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Zentalis Pharmaceuticals 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Meta 的痛苦可能是你的收益：这是一个罕见的买入窗口吗？</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>3 只低调的 AI 股票在下跌时值得购买</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>你的感恩节投资计划：3 只股票将受益于足球热潮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ZNTL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Zentalis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Zentalis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Zentalis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Zentalis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Zentalis Pharmaceuticals 并不在名单上。</p>
</div><p>While Zentalis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zentalis Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

华尔街禅将 Zentalis Pharmaceuticals（NASDAQ:ZNTL）的评级上调为持有